Home›Companies›Healthcare›Episteme Prognostics

Episteme Prognostics, Inc.

Develops tests to help clinicians predict cancer patients' responses to chemotherapy.

Updated Nov 9, 2026·Latest SEC filing Sep 4, 2026·Suggest an edit

About Episteme Prognostics

Episteme Prognostics is a private company based in Brooklyn, New York. It has reported $9,833,036 raised in four offerings on Form D since January 2022. Its chief executive is Surajit Dhara.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Aug 20, 2026Sep 4, 2026amended Sep 4, 2026$5,091,997of $6.0M target14$363KEquityRule 506(b)Form D/A ↗1 earlier filing
Feb 21, 2025Mar 10, 2025$550,000of $2.5M target1$550KOptionsRule 506(b)Form D ↗
Mar 31, 2023Apr 14, 2023amended May 22, 2023$4,111,039fully sold16$256KEquityRule 506(b)Form D/A ↗1 earlier filing
Dec 15, 2021Jan 3, 2022$80,000of $3.0M target5$16,000Debt, OptionsRule 506(b)Form D ↗
Total, four offerings$9,833,036

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Episteme Prognostics's Form D filed Sep 4, 2026.

GH
Gregory Ho
Board Member
Surajit Dhara
Surajit Dhara
Co-Founder, President, CEO, Board Member

Earlier filings also listed Robert Warren (director, last listed Mar 2025) and Marek Herrmann-Nowosielski (executive officer, last listed Jan 2022).

Sources

  1. SECEpisteme Prognostics, Inc. Form D, filed Sep 4, 2026
  2. SECEpisteme Prognostics, Inc. Form D, filed Apr 14, 2023
  3. SECEpisteme Prognostics, Inc. filing history
  4. CompanyAbout Episteme Prognostics
  5. CompanyContact Episteme Prognostics